Why the study?
While left ventricular systolic heart failure assessment is key in anthracycline-treated patients, less is known regarding the relevance and characterisation of left ventricular diastolic functional impairment.
Does anthracycline-based chemotherapy impair echocardiographic diastolic function parameters in breast cancer patients without previous cardiac disease?
Population
892 breast cancer patients without cardiac disease from 13 studies
Comparison
Echocardiographic parameters before vs after anthracycline-based chemotherapy
Design
Meta-analysis
Authors
Loading...
May warrant selective rather than routine diastolic monitoring post-anthracycline; extends evidence of limited early effects in low-risk patients.
Does anthracycline-based chemotherapy impair echocardiographic diastolic function parameters in breast cancer patients without previous cardiac disease?
Anthracycline-based chemotherapy has a modest early impact on the E/A ratio but does not significantly alter other diastolic parameters like EDT, e', or E/e' in breast cancer patients without prior cardiac disease.
Mincu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: